The AASD recommends lifestyle changes in the form of a reduced-calorie diet and increased physical activity, together with new anti-obesity medications, including GLP-1 RA and dual GIP/GLP-1 receptor agonists, as first-line treatment for patients with obesity, prediabetes, and type 2 diabetes. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.